Cipher Pharmaceuticals Inc Has Another Very Strong Trading Session

 Cipher Pharmaceuticals Inc Has Another Very Strong Trading Session

The stock of Cipher Pharmaceuticals Inc (TSE:CPH) is a huge mover today! About 38,250 shares traded hands or 28.46% up from the average. Cipher Pharmaceuticals Inc (TSE:CPH) has declined 56.16% since April 13, 2016 and is downtrending. It has underperformed by 60.09% the S&P500.
The move comes after 7 months positive chart setup for the $88.87M company. It was reported on Nov, 15 by Barchart.com. We have $6.47 PT which if reached, will make TSE:CPH worth $60.43 million more.

Cipher Pharmaceuticals Inc (TSE:CPH) Ratings Coverage

Out of 2 analysts covering Cipher Pharmaceuticals (TSE:CPH), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Cipher Pharmaceuticals has been the topic of 2 analyst reports since August 12, 2016 according to StockzIntelligence Inc. The stock has “Buy” rating given by TD Securities on Friday, August 12. On Friday, August 12 the stock rating was downgraded by GMP Securities to “Hold”.

More recent Cipher Pharmaceuticals Inc (TSE:CPH) news were published by: Prnewswire.com which released: “Cipher Pharmaceuticals Inc. Announces Changes to its Board of Directors” on August 09, 2016. Also Prnewswire.com published the news titled: “Cipher Pharmaceuticals Inc. announces Sitavigâ„¢ accepted for review by Health …” on February 16, 2016. Prnewswire.com‘s news article titled: “Cipher Pharmaceuticals acquires assets of Melanovus Oncology Inc.” with publication date: January 09, 2015 was also an interesting one.

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The company has a market cap of $88.87 million. The Firm has a portfolio of commercial and late-stage products. It currently has negative earnings. It operates in the specialty pharmaceuticals segment.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags:

Related posts

Leave a Comment